Sanofi strikes rare disease research deal; Roche pays $4M to drug-delivery partner;

@FierceBiotech: Pfizer hits recruitment rut in virtual clinical trial, seeks CRO to help with European edition of study. More | Follow @FierceBiotech

@JohnCFierce: Great time to sell to AZ. They're getting murdered in the clinic, need to load up on deals. Analysis | Follow @JohnCFierce

@RyanMFierce: FDA asked to treat anti-superbug drugs like rare disease meds. Story | Follow @RyanMFierce

@MarkHFierce: The stem cell juggernaut goes on: An injection during kidney transplant conquered rejection. Impressive. Article via BBC | Follow @MarkHFierce

> French drug giant Sanofi ($SNY), the owner of rare disease drug specialist Genzyme, has struck a pact with The Centre for Genomic Regulation in Spain to apply innovations in biomedicine to research genetic and rare diseases. Article

> Drug delivery specialist Haloyzme Therapeutics ($HALO) pocketed a $4 million milestone payment from Roche ($RHHBY), which paid the fee because it asked European regulators to give a nod to a new formulation of its cancer drug Herceptin that involves Halozyme's subcutaneous delivery tech. Release

> Peregrine Pharmaceuticals ($PPHM) seemed surprised to see the control arm of the developer's Phase II study of its drug bavituximab in lung cancer patients show longer-than-expected progression-free survival. Release

> Sangamo BioSciences ($SGMO) presented more data this week from its cellular therapy program that aims to provide a "functional cure" for HIV. Release

> The FDA asks advisers to consider whether drugmakers should get the green light to rekindle efforts to test pain drugs tied to joint failure. Article

Pharma News

@FiercePharma: If J&J's Zytiga can get pre-chemo indication in prostate cancer, patient pop is twice as big, analysts say. Article | Follow @FiercePharma

> Bayer Healthcare posts big growth in Asia Pacific. Story

> Generics deals drive increase in pharma M&A. Article

> With Seroquel petition denied, AZ needs M&A. Story

And Finally… Research finds that a wolf's loss (of life) is a moose's gain (of life). Item

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.